Juvenile Arthritis News

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

New recommendations from the American College of Rheumatology and the American College of Chest Physicians strongly advise against glucocorticoids for interstitial lung disease in systemic sclerosis.

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.

Infections account for most in-hospital mortality in childhood systemic lupus erythematosus, with patients exhibiting lupus nephritis or end-stage renal disease at increased risk, according to data published in The Journal of Rheumatology.

Lower levels of S100 proteins at baseline predict better treatment response with abatacept in patients with polyarticular-course juvenile idiopathic arthritis, according to data published in Arthritis Research & Therapy.

It may be possible to forecast persistent disease activity in juvenile idiopathic arthritis using C-reactive protein-to-albumin ratio and neutrophil-to-lymphocyte ratio, according to data published in BMC Rheumatology.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

ORLANDO, Fla. — Cognitive behavioral therapy can help children and adolescents with rheumatic diseases cope with the challenges of their condition, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

ORLANDO, Fla. — Allowing children with rheumatic diseases the time and space to formulate their own thoughts on their condition can facilitate communication and help them live a normal life, according to a presenter.